Insulet’s (Nasdaq:PODD) stock soared more than 20% today on first-quarter results that exceeded the consensus forecast.
Shares of PODD were trading at around $307 a share near the close of trading, the day after the company’s evening earnings report.
The Acton, Massachusetts–based automated insulin delivery technology maker reported profits of $35.4 million. That equals 50¢ per share on sales of $569 million for the three months ended March 31, 2025.
Insulet recorded a 31.3% bottom-line slide on a sales increase of 28.8%.
Adjusted to exclude one-time items, earnings per share came in at $1.02. That landed 23¢ ahead of expectations on Wall Street. Sales also topped estimates as experts forecast $543.3 million.
“Our first quarter results showcase the strong execution and dedication of the Insulet team, who has continued to expand the reach of Omnipod 5 technology to people living with diabetes globally. As Insulet’s new president and CEO, I see a path to scale the company from an emerging diabetes leader to a durable growth engine, driving an even greater impact for our partners, stakeholders, and most importantly, our podders,” said Ashley McEvoy, president and CEO. “I’d like to thank the team and board of directors for their incredible support. Insulet is just getting started on an exciting journey to revolutionize diabetes management globally. I am energized and honored to embark on that journey with all of you.”
Insulet expects overall sales to grow 19%-22% in 2025, with Omnipod sales set to increase 20%-23%.
The analysts’ take on Insulet
BTIG analysts Marie Thibault, Sam Eiber and Alexandra Pang maintained a “Buy” rating for Insulet following the quarterly results.
The analysts note that new patient starts grew both domestically and internationally in the quarter, with 85% coming from multiple daily injections (MDI). Additionally, the company set guidance above consensus for the coming second quarter, the analysts say.
“This bullish Q2 guide also implies markedly slower growth in 2H; more likely, the full-year outlook is conservative as new management awaits further evidence of momentum to hike its guidance again,” they wrote. “[Insulte] is well-positioned on macro uncertainty, with potential exemption and since most U.S. product is made in its Acton, Massachusetts facility.”
According to the analysts, Insulet can offset potential tariff impact, too. Meanwhile, the company’s “already-impressive margin outlook” could leave room for investments.
“New CEO Ashley McEvoy gave upbeat commentary on [Insulet’s] ability to keep advancing its commercial efforts and pipeline while supporting continued improvement in operating margin,” they wrote. “This quarter satisfied on all key metrics, combining a solid Q1 beat with a confident Q2 outlook and margin leverage.”
This story originally ran on May 8, 2025. Updated May 9 with next-day stock price.
